Literature DB >> 10514392

Increased mucosal production of monomeric IgA1 but no IgA1 protease activity in Helicobacter pylori gastritis.

A E Berstad1, M Kilian, K N Valnes, P Brandtzaeg.   

Abstract

Immunoglobulin A and IgM are subjected to epithelial transport only when they are produced as polymers with incorporated J chain. Immunocytes containing various Ig isotypes and associated J chain in gastric mucosa, as well as IgA-degrading protease activity in Helicobacter pylori cultures, were examined. Gastric body specimens from 15 H. pylori-positive and 14 H. pylori-negative patients were studied by paired immunofluorescence for IgA, IgA1, IgA2, IgG, or IgM and concurrent cellular J chain. H. pylori isolates were incubated with IgA1 or secretory IgA and examined by immunoelectrophoresis for cleavage products. A substantial increase of Ig-producing cells occurred in chronic gastritis, particularly in the IgA1 isotype, but H. pylori was shown to possess neither IgA1-specific nor nonspecific IgA-degrading protease activity. Regardless of infection status, reduced J chain expression was observed for all immunocyte isotypes (except for IgM) in inflamed compared with normal gastric body mucosa, the median positivity for IgA1 cells being reduced to 58.7% versus 87.9% (P = 0.0002), and for IgA2 cells to 48.9% versus 87.8% (P = 0.0002). This down-regulation of the J chain suggested that a large fraction of IgA monomers is produced in gastritis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514392      PMCID: PMC1867034          DOI: 10.1016/S0002-9440(10)65212-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  Immunoglobulin M and secretory immunoglobulin A: presence of a common polypeptide chain different from light chains.

Authors:  J Mestecky; J Zikan; W T Butler
Journal:  Science       Date:  1971-03-19       Impact factor: 47.728

2.  Different subclass distribution of IgA-producing cells in human lymphoid organs and various secretory tissues.

Authors:  K Kett; P Brandtzaeg; J Radl; J J Haaijman
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

3.  Prospective study of cancer in patients with hypogammaglobulinaemia.

Authors:  L J Kinlen; A D Webster; A G Bird; R Haile; J Peto; J F Soothill; R A Thompson
Journal:  Lancet       Date:  1985-02-02       Impact factor: 79.321

4.  Specific and nonspecific humoral defense factors in the epithelium of normal and inflamed gastric mucosa. Immunohistochemical localization of immunoglobulins, secretory component, lysozyme, and lactoferrin.

Authors:  K Valnes; P Brandtzaeg; K Elgjo; R Stave
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

5.  Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins.

Authors:  P Brandtzaeg; H Prydz
Journal:  Nature       Date:  1984 Sep 6-11       Impact factor: 49.962

6.  Immunohistochemical characterization of intracellular J-chain and binding site for secretory component (SC) in human immunoglobulin (Ig)-producing cells.

Authors:  P Brandtzaeg
Journal:  Mol Immunol       Date:  1983-09       Impact factor: 4.407

7.  Immunoglobulin A (IgA).

Authors:  J Mestecky; M Kilian
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

8.  Prolonged incubation time in immunohistochemistry: effects on fluorescence staining of immunoglobulins and epithelial components in ethanol- and formaldehyde-fixed paraffin-embedded tissues.

Authors:  P Brandtzaeg
Journal:  J Histochem Cytochem       Date:  1981-11       Impact factor: 2.479

9.  Significance of different J chain profiles in human tissues: generation of IgA and IgM with binding site for secretory component is related to the J chain expressing capacity of the total local immunocyte population, including IgG and IgD producing cells, and depends on the clinical state of the tissue.

Authors:  P Brandtzaeg; F R Korsrud
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

10.  Systemic and local antibody responses to gastric Campylobacter pyloridis in non-ulcer dyspepsia.

Authors:  B J Rathbone; J I Wyatt; B W Worsley; S E Shires; L K Trejdosiewicz; R V Heatley; M S Losowsky
Journal:  Gut       Date:  1986-06       Impact factor: 23.059

View more
  6 in total

Review 1.  Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses.

Authors:  Holly M Scott Algood; Timothy L Cover
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 2.  Helicobacter pylori interactions with host serum and extracellular matrix proteins: potential role in the infectious process.

Authors:  J Daniel Dubreuil; Giuseppe Del Giudice; Rino Rappuoli
Journal:  Microbiol Mol Biol Rev       Date:  2002-12       Impact factor: 11.056

3.  Contribution of secretory antibodies to intestinal mucosal immunity against Helicobacter pylori.

Authors:  Rebecca J Gorrell; Odilia L C Wijburg; John S Pedersen; Anna K Walduck; Terry Kwok; Richard A Strugnell; Roy M Robins-Browne
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

4.  Helicobacter pylori cag pathogenicity island's role in B7-H1 induction and immune evasion.

Authors:  Taslima T Lina; Shatha Alzahrani; Jennifer House; Yoshio Yamaoka; Arlene H Sharpe; Bill A Rampy; Irina V Pinchuk; Victor E Reyes
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

5.  Putative consequences of exposure to Helicobacter pylori infection in patients with coronary heart disease in terms of humoral immune response and inflammation.

Authors:  Agnieszka Matusiak; Maciej Chałubiński; Marlena Broncel; Tomasz Rechciński; Karolina Rudnicka; Eliza Miszczyk; Maria Walencka; Dominik Strapagiel; Adrian Gajewski; Magdalena Chmiela
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

Review 6.  Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis.

Authors:  Atsushi Takahashi-Kanemitsu; Christopher T Knight; Masanori Hatakeyama
Journal:  Cell Mol Immunol       Date:  2019-12-05       Impact factor: 11.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.